Nabriva Therapeutics plc (NBRV) |
|
1.47 -0.03 (-2%)
|
06-09 14:28 |
|
Open: |
1.5012 |
Pre. Close: |
1.5 |
|
High:
|
1.52 |
Low:
|
1.46 |
|
Volume:
|
7,810 |
Market Cap:
|
5(M) |
|
|
|
Technical analysis |
as of: 2023-06-09 2:46:29 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 2.23 One year: 2.61 |
| Support: |
Support1: 1.38 Support2: 1.15 |
| Resistance: |
Resistance1: 1.91 Resistance2: 2.24 |
| Pivot: |
1.58 |
| Moving Average: |
MA(5): 1.47  MA(20): 1.61
MA(100): 1.64 MA(250): 2.61 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 11 %D(3): 9.8 |
| RSI: |
RSI(14): 43.6 |
| 52-week: |
High: 8.44 Low: 1.21 |
| Average Vol(K): |
3-Month: 14 (K) 10-Days: 13 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NBRV ] has closed above bottom band by 27.0%. Bollinger Bands are 30.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.53 - 1.54 |
1.54 - 1.55 |
|
Low:
|
1.5 - 1.51 |
1.51 - 1.52 |
|
Close:
|
1.52 - 1.53 |
1.53 - 1.54 |
|
Company Description |
|
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland. |
Headline News |
Wed, 07 Jun 2023
Should You Add Nabriva Therapeutics PLC - ADR (NBRV) Stock to Your Portfolio Wednesday? - InvestorsObserver
Thu, 04 May 2023
Revance Therapeutics Inc (RVNC) Stock: What Does the Chart Say Thursday? - InvestorsObserver
Wed, 03 May 2023
Is Nabriva Therapeutics PLC - ADR (NBRV) Stock Worth a Buy Wednesday? - InvestorsObserver
Thu, 20 Apr 2023
Should You Hold Windtree Therapeutics Inc (WINT) Stock Thursday Morning? - InvestorsObserver
Wed, 19 Apr 2023
Do Traders Think Nabriva Therapeutics PLC - ADR (NBRV) Can Keep Climbing Wednesday? - InvestorsObserver
Mon, 17 Apr 2023
NABRIVA THERAPEUTICS PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
3 (M) |
| Shares Float |
3 (M) |
|
% Held by Insiders
|
0.4 (%) |
|
% Held by Institutions
|
9.2 (%) |
|
Shares Short
|
25 (K) |
|
Shares Short P.Month
|
23 (K) |
Stock Financials |
|
EPS
|
-17.24 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-1.37 |
|
Profit Margin (%)
|
-148.2 |
|
Operating Margin (%)
|
-143.6 |
|
Return on Assets (ttm)
|
-72.7 |
|
Return on Equity (ttm)
|
-268.6 |
|
Qtrly Rev. Growth
|
-5.5 |
|
Gross Profit (p.s.)
|
-3.2 |
|
Sales Per Share
|
11.4 |
|
EBITDA (p.s.)
|
-16.33 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-26 (M) |
|
Levered Free Cash Flow
|
-6 (M) |
Stock Valuations |
|
PE Ratio
|
-0.09 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-1.09 |
|
Price to Sales
|
0.12 |
|
Price to Cash Flow
|
-0.18 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
